It’s time to get involved: EUnetHTA publishes the second iteration of the EUnetHTA Prioritisation List (EPL)
EUnetHTA’s Joint Action 3 will definitely end in 2020. However, all joint assessments started in the course of Joint Action 3 will be finalized – even beyond 2020. The methodology underlying the upcoming EU HTA will be strongly shaped by the methods and guidance currently applied in Joint Action 3. This makes 2019 the perfect time for pharmaceutical companies to join EUnetHTA’s Relative Effectiveness Assessment (REA) programme. Participation is the perfect opportunity to prepare for the future - the process allows exploring cooperative and multi-national clinical assessments with the involvement of various HTA authorities.
The AMS Medical Science Team is the ideal partner to accompany you through this process. We have continuously expanded our services in the area of European joint assessments and can draw on our experience gained from participation in a complete joint assessment process in EUnetHTA’s Joint Action 3. Our hands-on experience has enabled us to optimise our internal processes. Hence, we can perfectly advise you, aid you to work time- and cost-efficiently and thereby significantly contribute to your success.